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ABSTRACT 
Objective: The objective of the present study was to formulate and characterize paclitaxel (Ptx) loaded sterically stabilized emulsomes to provide 
non-toxic and biocompatible carriers with high Ptx loading efficiency.  
Methods: Plain (P-Es) and sterically stabilized emulsomes (SS-Es) were prepared by a modified solvent evaporation method using tristearin as 
solid lipid and optimized for lipid to (DSPC+CHOL+DSPE-PEG)/ tristearin ratio, lipid/lipid-PEG (DSPC+CHOL/DSPE-PEG) molar ratio, solid lipid 
concentration, phospholipid concentration, organic to aqueous phase volume and homogenization time based on their effect particle size and 
entrapment efficiency. Optimized emulsomes were characterized for morphological features, in vitro drug release kinetics and protection from 
plasma protein. 
Results: The emulsomes so formed were uniform in size with a mean particle diameter of 275±5.52 and 195±6.4 nm for P-Es and SS-Es 
respectively. All the formulations showed pH dependent drug release with a slow and sustained release profile. Slower drug release was observed 
from sterically stabilized emulsomes than the plain emulsomes. The drug release profile followed the Higuchi model with the Fickian diffusion 
pattern. The Pegylation of emulsomes significantly reduced the in vitro protein absorption.  
Conclusion: The sterically stabilized emulsome can serve as a novel non-toxic platform with longer circulatory time for the delivery of Paclitaxel 
and other poorly water-soluble drugs as well. 
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INTRODUCTION 
Development of nanotechnology-based novel carriers has 
revolutionized the field of drug delivery. The nanocarrier offers 
ample opportunities to be modified and functionalized to suit the 
physicochemical requirements of individual drug entities thereby, 
allowing administration of almost all types of chemotherapeutics 
and biological molecules. In the recent decade, continuous efforts 
are being focused on nanocarrier based tumorspecific anticancer 
drug delivery to minimize systemic leakage. Most of the approved 
anticancer drugs are lipophilic which presents solubility problems in 
preparing pharmaceutically acceptable formulation with maximum 
efficacy and minimum toxicity [1, 2]. Co-solvents based techniques 
are most widely used to improve the solubility of poorly soluble 
drugs, which are reported to cause toxic effect and hypersensitive 
reactions upon administration [3]. Extensive research on 
nanoparticles has resulted in drug delivery systems capable of 
protecting bioactive, improve solubility, minimize leakage and avoid 
the use of toxic solubilizers. Most of these nanovehicles are 
comprised of polymer or lipid or polymer-lipid hybrid. Paclitaxel is 
the most widely used taxane for the treatment of a wide variety of 
tumors [4, 5]. Its intravenous formulation is marketed as Taxol® 
wherein Cremophor EL and ethanol (50:50 v/v) are used as a 
solubilizer. Cremphor is associated with several side effects 
rendering Taxol® clinically unacceptable [6]. To overcome this 
limitation emulsomes based formulation is proposed. Emulsomes 
have emerged to provide a biocompatible platform along with the 
potential to accommodate lipophilic drugs in large amount. They are 
comprised of two structural components, a lipidic core made from 
solidified fatty acid and phospholipid/s forming stabilizing envelope 
around the core, act as a stabilizer. The fatty core can hold 
hydrophobic drugs in a higher amount [7]. Pharmaceutically stable 
emulsomal formulation can be prepared without the need for 
additional surfactant or solubilizer. The lipophilic drug is well 
retained within the lipidic core of emulsome resulting in minimum 
leakage into systemic circulation thereby, safeguarding the healthy 
tissue from unwanted side effects. Furthermore, the surface 
phospholipid of emulsomes can be easily pegylated to enhance 
stability and residence time in blood circulation. The conventional 
anticancer dosage forms present the issue of poor patient compliance 
because of repeated dosing requirements. Hence, nanocarriers are 
designed to provide controlled drug delivery at the tumor site with 
desired release kinetics for a prolonged period ranging from days to 
years. The formulation is intended to function as a biocompatible drug 
carrier providing prolonged drug release, minimum systemic leakage 
and reducing dosing frequency with better patient compliance. The 
Ptx release pattern from emulsomes will be analyzed by fitting in vitro 
drug release data into various mathematical kinetic models. Therefore, 
in the present study, Ptx loaded sterically stabilized emulsomes are 
envisaged as a potential drug delivery system for the anticancer drug 
with predictive drug release kinetics.  
MATERIALS AND METHODS 
Materials 
Paclitaxel was obtained as a gift sample from Neon laboratories ltd. 
Mumbai, India. DSPC and Cholesterol and DSPE-PEG were obtained 
as a gift sample from Lipoid Gmbh, Germany. Tristearin was 
purchased from Sigma Aldrich Chemie, Gmbh. All other reagents and 
chemicals used were of analytical grade and purchased from a local 
chemical supplier. 
Methods 
Formulation of plain emulsomes (P-Es) and sterically stabilized 
emulsomes (SS-Es) 
Plain (P-Es) and sterically stabilized emulsomes (SS-Es) were 
synthesized from tristearin (solid lipid core), DSPC and cholesterol 
(outer stabilizing envelope) and DSPE–PEG (steric stabilizer) using a 
modified single emulsification-solvent evaporation method resulting 
in self-assembly [8, 9]. Weighed ratios of solid lipid were melted at 
80 °C and then the drug previously dissolved in aqueous ethanolic 
solution (5 ml) was added to it under constant stirring (1000 rpm) 
on a magnetic stirrer while maintaining the temperature to 80°C. 
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The solution was stirred for 15 min at 1000 rpm to form 
homogeneous dispersion. Phospholipids and DSPE-PEG (for SSE) 
were dispersed in distilled water, heated to the same temperature 
and then stirred vigorously for 10 min at 80 °C at 5000 rpm. The 
organic phase was added dropwise (1 ml/min) into the aqueous 
phase while maintaining the temperature at 80 °C. After complete 
addition of the organic phase, the emulsion was stirred vigorously 
for 30 min at 10,000 rpm. The resulting emulsion was cooled to 4 °C 
on an ice bath resulting in the assemblage of phospholipids around 
the solid lipid core followed by the evaporation of the organic 
solvent. The emulsion was dialyzed using a dialyzing membrane 
with a molecular weight cut off of 10kDa to remove the remaining 
organic solvent and free molecules. The dispersion was sterilized by 
filtering through a filter unit with a 0.22 micrometer pore size. The 
emulsomes were then lyophilized using 5% sucrose as 
cryoprotectant and stored at 4 °C until use. 
Optimization of emulsome formulations 
Each of the emulsome formulations was optimized for phospholipid 
(PL: DSPC+CHOL+DSPE-PEG)/solid lipid (SL: tristearin ratio), 
lipid/lipid-PEG (DSPC+CHOL/DSPE-PEG) molar ratio, solid lipid 
concentration, phospholipid concentration, organic to aqueous 
phase volume and homogenization time based on their effect 
particle size (PS) and entrapment efficiency (EE). 
Characterization of emulsome formulation 
Vesicle size and size distribution  
Maintaining constant size and size distribution for a prolonged period 
is an indication of stability of emulsome. Electron microscopy is widely 
used for the assessment of surface morphology, size and size 
distribution of emulsomes. Besides the routine laboratory techniques 
such as gel chromatography etc., techniques based on light scattering 
and electron microscopy are needed to be applied for the statistically 
significant analysis of size and size distribution of the carriers. 
The average vesicle size and size distribution were determined by 
photon correlation spectroscopy using zetasizer (Nanoplus 5.01, 
particulate system). The sample of dispersion was diluted to 1:9 ratio 
with deionized water. The vesicle size distribution graph is represented 
by the average vesicle size (diameter) and polydispersity index. 
Zeta potential 
The zeta potential of a particle is the overall charge that the particle 
acquires in a particular medium. The knowledge of the zeta potential 
can help to predict the fate of the preparation in vivo and assess the 
stability of colloidal systems. Zeta potential of emulsome 
formulations was determined by photon correlation spectroscopy 
using Zetasizer Nanoseries (Nanoplus 5.01, particulate system) 
using a flow-through cell. 
Shape and surface morphology 
Shape and surface morphology of emulsome was determined by 
Transmission Electron Microscope (TEM) technique. The sample (10 
μl) was placed on the grids and allowed to stand at room temperature 
for 90 s. Excess of the fluid was removed by touching the edge filter 
paper. All samples were examined under a transmission electron 
microscope (Tecnai G2, Hillsboro Oregon, USA) at an acceleration 
voltage of 100 kV and photomicrographs were taken at 1400X. The 3D 
view of the prepared emulsomes was photographed by Scanning 
Electron Microscopy, (SEM, NOVA NanoSEM 450). 
Entrapment efficiency 
Entrapment Efficiency of emulsome was determined using the 
method prescribed by Vyas et al., 2006 [10]. This method includes 
separation of unentrapped drug-using mini centrifuge column of 
Sephadex G-50 and then evaluate entrapment efficiency by 
disrupting the vesicle in a suitable solvent as given below. 
Preparation of sephadex G-50 gel preparation 
Sephadex G-50 (1.2 g) was allowed to swell in 20 ml of 0.9% NaCl 
solution for 5 h at room temperature with occasional shaking. The 
gel so formed was stored at 4 °C. 
Preparation of mini-column  
The hydrated gel was filled to the top in the barrel of 1 ml disposable 
syringe plugged with a Whatman filter pad. The barrels were placed 
in the centrifuge tubes, centrifuged at 2000 rpm for 3 min to remove 
the excess saline solution. 
Entrapment efficiency determination 
Eluted volume was removed from the centrifuged tubes and exactly 
0.2 ml of emulsome suspension (undiluted) was applied dropwise 
on the gel bed in the center. Columns were again centrifuged at 2000 
rpm for 3 min to expel and remove void volume containing 
emulsome into the centrifuge tubes. Elute was removed and 0.25 ml 
of saline was applied to each column and centrifuged as previously. 
The amount of drug entrapped in the vesicle was then determined 
by disrupting the vesicle using 1 ml of 0.1% v/v Triton-X 100, 
filtering it and the drug content was determined using UV-Vis 
spectroscopy at 229 nm. The percentage efficiency was determined 
by the following equation:  
Entrapment Ef�iciency (%)
=
Total amount of drug − amount of drug lost
Total amount of drug  × 100 
In vitro drug release profile 
The in vitro Ptx release from the vesicle was investigated at a 
temperature of 37±1 C° using phosphate buffer pH (4.0) as dialysis 
media. 1 ml of drug-loaded vesicle suspension was placed in a 
dialysis membrane separately and dialyzed against 20 ml of 
phosphate buffer pH (4.0). The samples (1 ml each) were withdrawn 
periodically up to 24 hr and then the withdrawn volume was 
replaced immediately with fresh buffer media. The withdrawn 
sample was analyzed spectrophotometrically at 229 nm for Ptx. 
Drug release kinetics study 
The kinetic profile of paclitaxel release from emulsomes was 
determined by applying the data obtained from in vitro drug release 
study into various mathematical kinetic models namely zero order, 
first release, Higuchi model and Korsmeyer-Peppas model. The 
parameters like regression coefficients and drug release rate 
constants were compared to understand the release mechanism 
from emulsomes. ‘n’ value calculated from Korsmeyer-Peppas model 
suggests the type of diffusion pattern followed by the drug. 
In vitro plasma protein absorption study 
To study the influence of PEG as a stealth layer, in vitro plasma 
protein absorption study was performed. Emulsomal formulations 
were incubated in 5% bovine serum albumin and observed for 
change in particle size and size distribution due to protein 
adsorption using zetasizer. 
Data analysis 
All the results from the studies are average of triplicate experiments 
(n=3) at a given time point. The observations were tested 
statistically using one-way analysis of variance ANOVA followed by 
Turkey-Kraner test using graph pad prism software (version 3.00, 
Graph pad Software, San Diego, California, USA). Results were 
expressed as mean±standard deviation (SD). A difference of p<0.05 
was considered statistically significant. 
RESULTS AND DISCUSSION 
Modified solvent evaporation was used to prepare the emulsomes in 
which tristearin was incorporated to form hydrophobic solid core; 
polyethylene glycol (PEG) which is covalently conjugated to 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) forms the 
stealth shell around emulsomes for avoiding particle agglomeration; 
and DSPC and cholesterol which formed a stabilizing envelope 
around the hydrophobic core. Specifically, solid lipid precipitates to 
form the lipidic core which entraps the poorly-water soluble drug, 
Paclitaxel; DSPC, Chol and DSPE-PEG assemble around the core to 
form a lipid monolayer/multilayer offering sufficient stability to the 
emulsomes avoiding the need to incorporate surfactant to form 
stabilized formulation. Table 1 describes the composition of both 
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types of emulsome formulations. The method of preparation 
resulted in uniform emulsome formulation with narrow size 
distribution as indicated by a significant p-value of<0.01 for 
polydispersity index (table 2). 
 
Table 1: Composition of optimized formulations 










P-Es - 1:1 1:10 10 15 
SS-Es 1:3 1:1 1:10 10 15 
P-Es: Plain emulsomes, SS-Es: Sterically stabilized emulsomes, PL: phospholipid, DSPE-PEG: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-
Poly(ethyleneglycol), SL: Solid lipid 
 
Table 2: Physicochemical properties of optimized formulations 
Formulation code Size (nm) PI Zeta potential (mV) %EE 
P-Es 275±5.52* 0.112±0.011** -30.5±2.0* 72.54±3.41* 
SS-Es 195±6.4** 0.124±0.012** -35.8±2.1* 75.56±3.25** 
Data represents mean±SD (n=3), *Statistically significant difference at *p<0.05,** Statistically significant difference at p<0.01 
 
Formulation variables for the optimization of emulsomes 
The formulations were optimized based on the effect of lipid/lipid-
PEG (DSPC+Chol/DSPE-PEG) molar ratio, total lipid to 
(DSPC+Chol+DSPE-PEG)/solid lipid (tristearin) mass ratio, the effect 
of solid lipid concentration (tristearin), the effect of phospholipid 
concentration, the effect of organic to aqueous phase volume ratio 
on the particle size (PS) and entrapment efficiency (%EE). The 
formulation variables which resulted in the small size of particles 
with higher drug entrapment were taken as optimized formulations. 
Effect of PL/DSPE-PEG molar ratio on particel size (PS) and 
entrapment efficiency (EE%) 
DSPE-PEG is known and used for providing steric stabilization to the 
nanocarrier systems. The study conducted revealed that the size of 
the emulsomes was reduced with the addition of DSPE-PEG. The size 
of the plain emulsomes without DSPE-PEG was found to be 
320.5±5.8 nm (fig. 1). The particle size of SS-Es was found to 
decrease from 320.5±5.8 nm to 190.5±4.77 nm when the PL to 
DSPE-PEG molar ratio was changed from 1:0 to 1:5. The size of 
emulsomes at 1:3 molar ratio was found to be significantly lower 
(p<0.01) as compared to plain emulsomes with a mean particle 
diameter of 195.5±5.6 nm. No significant difference in the size of 
emulsomes was found on increasing the ratios from 1:3 to 1:5. 
Hence, 1:3 was taken as an optimized ratio. The decrease in size was 
owing to the presence of the PEG on the surface of the emulsomes 
which could prevent the aggregation of the nanoparticles as the 
pegylated hydrophilic end of the DSPE-PEG provides steric 
hindrance to the particles [11]. The percentage entrapment 
efficiency (%EE) was found to be 78.20±2.8 at 1:3 for SS-Es (fig. 1 
A.). The sterically stabilized emulsomes so formed had a relatively 
low polydispersity index indicating narrow size distribution. The 
zeta potential value of the formulation was sufficiently (-32 mV) 
high (p<0.01) signifying a thermodynamically stable formulation 
with minimum agglomeration. The higher zeta potential infers 
highly charged particles that remain separated due to electric 
repulsion, preventing the formation of coagulate upon storage. The 
zeta potential of formulations was found in accordance with the 
reported literature which recommends the ZP value of 
approximately-30 mV is considered optimum for attaining stable 
nanoformulation [12].  
Effect of organic to aqueous phase volume ratio on particle size 
and entrapment efficiency 
The aqueous phase volume was varied from 5 to 20 ml whereas the 
organic phase was kept constant. Increasing the volume of the 
aqueous phase first resulted in a decrease in particle size followed by 
an increase in size later. The decrease in particle size could be due to 
larger external space for the dispersal of microdroplets avoiding 
collision and consequent aggregation [13]. The decrease in particle 
size resulted in increased entrapment efficiency because of the larger 
particle surface area. Further increment in aqueous volume would 
reduce the net shear applied on the emulsomes under constant 
external energy input leading to increased particle size later. 
The entrapment efficiency was found to decrease with the 
increasing volume of the aqueous phase which occurred because the 
amount of drug partitioning in the organic phase reduced during 
emulsification while the drug loss increased with the evaporation of 
the aqueous phase [14].  
The size of P-Es and SS-Es reduced from 270.5±2.5 nm to 230.2±3.5 
nm and 256.5±2.6 nm to 195.5±3.28 nm with the change in ratio from 
1:2 to 1:10 (fig. 2). On further increasing the aqueous phase volume 
the size was increased and hence, ratio 1:10 was selected as the 
optimum ratio. The entrapment efficiency at optimum ratio was found 




Fig. 1: A. Graphs showing the effect of PL to DSPE-PEG ratio on 
size and entrapment efficiency of emulsomes. B. Plot showing 
the change in zeta potential of emulsomes on the addition of 
DSPE-PEG to PL. Data represents mean±SD (n=3) 
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Fig. 2: Graph showing the effect of organic to aqueous phase 
volume on size and entrapment efficiency of emulsomes. Data 
represents mean±SD (n=3) 
 
Effect of PL to SL ratio on particle the size and entrapment 
efficiency EE% 
The size of the emulsomes was found to decrease from 650.5±1.5 
nm to 310.2±2.5 nm and 556.4±3.5 to 235.5±3.6 nm for P-Es and SS-
Es respectively when the ratio of PL: SL was varied from 0.25:1 to 
1.5:1 At 0:1 ratio of PL/SL, the formulation was pure lipidic 
nanoparticles which aggregated immediately to form larger particles 
of about 840.5±3.7 and 650.8±4.5 nm (fig. 3 A). The addition of PL in 
higher concentration allowed the formation of stable and nanosized 
emulsomes wherein the solid lipid formed the core and the 
phospholipids formed a stabilizing envelope around it. The ratio of 
0.25:1 to 0.5:1 resulted in particles with a larger size and a small 
zeta potential value (fig. 3 B). This might occur because the former 
ratio might not be covering the core completely resulting in unstable 
emulsomes with lower zeta potential values at which the particle 
formed aggregates. At the smaller value of zeta potential van der 
Waals attractive forces dominated the repulsive force leading to 
flocculation and particle aggregation [15]. As the ratio was increased 
above 0.5:1 to 1:1, the emulsomes formed were small and stable 
with the size range of 310.2±2.5 nm (zeta potential value of-32±0.12 
mV) and 235.5±3.6 nm (zeta potential-35±0.15 mV) for P-Es and SS-
Es with and respectively. It is reported that nanoparticles with a 
large negative or positive value of zeta potential are less prone to 
aggregation or increase in particle size indicating good physical 
stability [16, 17]. Hence, a higher zeta potential value of emulsome 
ascertains the thermodynamic stability of Ptx loaded emulsomal 
system. Thus at the 1:1 ratio of PL: SL, the concentration of PL 
reached the value at which the core was completely surrounded by 
the phospholipid envelope reducing the interfacial tension between 
lipid core and aqueous phase consequently favoring the formation of 
emulsomes with smaller size and sufficient electrostatic repulsion 
resulting in a relatively stable formulation [18]. On the other hand, 
all PL do not get incorporated in the particles when 30% lipid is 
employed resulting in the formation of vesicles in addition to 
emulsomes. Thus, the optimal PL amount of PL that yields stable and 
desired nanoparticles are with 20% PL: SL. As the ratio of PL was 
increased to a higher range, the excess lipids content may reach the 
value above CMC of (~ 0.4 mg/ml) resulting in the assembly of 
liposomes. This result in an overall increase in the size of the 
emulsomes and lowered the zeta potential value. Conversely, when 
the PL to SL ratio is too low the paucity of lipid leaves the core 
uncovered resulting in a higher zeta potential value. 
 
 
Fig. 3: A. Graphs showing the effect of PL to SL ratio on size and entrapment efficiency of emulsomes. B. Plot showing the change in the 
zeta potential of emulsomes with PL: SL ratio. Data represents mean±SD (n=3) 
 
 
Fig. 4: Graphs showing the effect of SL concentration on particle size and entrapment efficiency of emulsomes. Data represents mean±SD (n=3) 
 
Effect of solid lipid concentration on particle size and 
entrapment efficiency 
As the concentration of the solid lipid was increased from 5% to 
20%w/w the size of emulsomes was found to increase from 
198.5±4.5 nm to 380.4±2.4 nm and 182.3±3.5 nm to 358.5±1.5 nm 
for P-Es and SS-Es formulations respectively (fig. 4). This increase in 
size can be attributed to the increase in the viscosity of the organic 
phase and reduction in spontaneous diffusion of lipid in the aqueous 
phase as the concentration of solid lipid was increased. As the 
concentration of the core lipid was increased beyond 10%w/w, the 
PL becomes insufficient to completely cover the core resulting in the 
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coalescence of the lipid and instability with an increase in the 
diameter of the particles decreased entrapment efficiency. 
The entrapment efficiency of the drug was found to increase with the 
increase in solid lipid content because with the increased viscosity of the 
medium the drug diffusional resistance into the aqueous phase 
increased resulting in higher drug entrapment in the hydrophobic core. 
The higher drug loading efficiency with the increase in solid core content 
suggests a high affinity between Ptx and tristearin [19]. 
Effect of homogenization time on particle size and entrapment 
efficiency 
The addition of energy is an important factor that governs the 
emulsification process. To study the influence of this factor on 
particle size and size distribution homogenization time was varied 
from 5 to 15 min. An increase in homogenization time resulted in a 
progressive decrease in the mean diameter of emulsomes and 
narrow size distribution (fig. 5). The increase in energy input with 
time caused the rapid formation of nanosized core lipid droplets 
with a narrow polydispersity index. However, on further increasing 
sonication time particle size was found to increase. This could be 
ascribed to turbulent flow which increases the velocity of the 
medium leading to collision of the particles, formation of 
agglomerates and decreased entrapment efficiency [20]. The size of 
P-Es and SS-Es at optimized sonication time was found to be 
250.5±2.5 nm and 215.6±2.3 respectively and entrapment efficiency 
at optimized concentration was found to be 76.4±3.2 and 80.2±2.8 
for P-Es and SS-Es respectively. 
Physicochemical properties of emulsomes 
The composition and process variables at which optimized 
formulation was obtained are shown in table 1. The optimized 
formulations were characterized for various parameters like shape, 
size and zeta potential. The various physicochemical parameters are 
summarized in table 2. TEM and SEM micrograph shows the 
spherical geometry of emulsomes (fig. 6 A and B). Emulsomes 
formed were uniform in size as suggested by lower values of 
polydispersity index. The mean particle diameter of P-Es and SS-Es 
were in the range of 275±5.52 and 195±6.4 nm (fig. 7 A and B). The 
zeta potential of P-Es and SS-Es was found to be-30.5±2.0 and-
35.8±2.1 respectively (fig. 7 C and D). 
 
 
Fig. 5: Graphs showing the effect of homogenization time on the 
particle size of emulsomes, data represents mean±SD (n=3)
 
 
Fig. 6: A. Tem micrograph of SS-Es. The outer light periphery indicated by the arrow shows the presence of PEG on the surface of 




Fig. 7: Plots showing the size distribution of A. P-Es; B. SS-Es and zeta potential value of C. P-Es; D. SS-Es. 
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In vitro drug release 
The most desirable feature of an anticancer formulation is the ability 
to remain stable at physiological pH while releasing their payloads at 
the tumor site (acidic pH) [21]. Hence, in vitro drug release studies 
were performed at physiological pH (7.4) and tumor pH (4.0). 
The various formulations followed similar drug release profile at 
physiological and acidic pH which suggests that lipids and DSPE-PEG 
do not alter the drug release kinetics The studies revealed that the 
drug release from P-Es and SS-Es was found to be 40.5±2.7% and 
32.5±1.5% respectively in PBS pH 7.4 on the first day (24 h) (fig. 
8A). The initial burst release could be attributed to the rapid release 
of phospholipid associated Ptx. The cumulative drug release then 
followed a sustained and slow release pattern for 7 d. The 
cumulative drug release during the next 6 d was recorded to be 
75.50±4.5% and 66.80±3.5% from P-Es and SS-Es respectively.  
The slower release from SS-Es as compared to P-Es was ascribed to 
be due to the presence of pegylated surface layer on the emulsomes 
which resisted the structural change and remain rigid preventing 
the entry of solvent molecules to the lipidic core. The drug release 
was faster at acidic pH (pH 4.0) from both the formulations with 
values of 52.5±1.5% and 48.6±2.5% respectively during 24 h. This 
faster release as compared to pH 7.4 suggests pH-dependent 
behavior of the system. The Ptx is released slowly at 7.4 indicating 
most of the molecules remain within the emulsomes, thereby 
reducing systemic toxicity. The initial higher drug release from these 
formulations over 24 h as compared at acidic pH was because of 
disassociation of the phospholipid bilayer in the acidic medium 
providing larger space for the drug to diffuse out easily and also 
allows entry of larger number of solvent molecules. The entry of 
water into the system results in hydrolysis of core, erosion and 




Fig. 8: Plot showing the in vitro drug release kinetics as per the various mathematical models A. Zero order drug release model. B. First 
order drug release model. C. Higuchi model D. Korsmeyer-peppas model. Data represents mean±SD (n=3) 
 
Drug release kinetics study  
The in vitro cumulative percentage drug release data were analyzed 
using mathematical kinetic models for studying the release pattern 
of Ptx. Various graphs representing a particular kinetic model were 
plotted to assess the mechanism and kinetics of drug release (fig. 8). 
The graphs were plotted between cumulative percentage drug 
release (Q) vs time (t), log cumulative percentage drug remaining vs 
t, cumulative percentage drug release (Q) vs √𝑡 and log cumulative 
percentage drug release vs log t for zero oreder, first order, Higuchi 
model and Korsmeyer-Peppas model respectively. The regression 
coefficients obtained in each case were compared to find out the 
model which was best suited the drug release pattern from 
emulsomes (table 3). The highest value of regression coefficient ‘R’ 
from the plot of Q vs √t reveals drug release followed Higuchi kinetic 
model which implies diffusion controlled drug release from 
emulsome. Korsmeyer-Peppas model was applied to state the type 
of diffusion, which depends on the value of diffusion coefficient ‘n’ 
(slope). Then n value was found to be less than 0.5 suggest Fickian 
transport of the drug [22]. 
 
Table 3: Parameters for kinetic models applied to in vitro drug release data from emulsome formulations 
Formulation Zero order First order Higuchi Korsmeyer-peppas 
R2 K R2 K R2 K R2 n 
P-Es (pH 7.4) 0.8875 0.3011 0.9512 0.0025 0.9947 4.4170 0.9766 0.3252 
SS-Es (pH 7.4) 0.9470 0.3166 0.9755 0.0024 0.9912 4.5573 0.9925 0.3942 
P-Es (pH 4.0) 0.9128 0.3255 0.9766 0.0033 0.9958 5.5072 0.9968 0.2659 
SS-Es (pH 4.0) 0.9383 0.2860 0.9755 0.0022 0.9997 4.3476 0.9858 0.2730 
R: regression coefficient. K: release constant, n: diffusion coefficient  
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Plasma protein absorption study  
The major obstacle in achieving long circulatory nanocarriers is 
their recognition and clearance by the Reticulo-endothelial system 
(RES). The protein opsonin gets absorbed on the surface of 
nanoparticles which facilitates identification by the macrophages 
followed by phagocytosis. DSPE-PEG incorporated in the PL 
envelope of emulsomes confers stealth property, safeguarding them 
from RES uptake and prolonging circulatory time. Analysis of the 
stealth property was performed by incubating emulsome 
formulation in 5% bovine serum albumin and distilled water as a 
control for a definite period of time and observing the change in 
their particle size and particle size distribution. The mean diameter 
of both the formulation remained unchanged after 24 h in distilled 
water. After 12 h of incubation in BSA the particle size of P-Es and 
SS-Es remained unchanged. However, 24 h later a prominent change 
in the size of P-Es was observed with the size of 575±2.5 nm 
signifying protein absorption on the emulsomes while the size of SS-
Es was slightly changed indicating smaller protein absorption (fig. 
9). The data indicate pegylation limits the protein absorption 
tendency, hence acts as a stealth layer protecting the nanosystem 




Fig. 9: Change in size of emulsomes on incubation with 5%BSA, 
data represents mean±SD (n=3) 
 
CONCLUSION 
Formulation of clinically acceptable Ptx formulation is challenging 
owing to its poor aqueous solubility and lower bioavailability. 
Compritol based emulsomes were studied as an alternative to 
cremphore based formulation to provide a biocompatible and safe 
nanocarrier for delivery of Ptx. The drug can be easily entrapped 
within the solid lipid core without the use of any additional 
solubilizer/surfactant or co-solvent. The outstanding feature of the 
system lies in its ability to form stable nanoformulation without the 
need for surfactant. The phospholipids envelope surrounding the 
solid lipid core acts as a natural stabilizer. The emulsomes were 
successfully synthesized by the modified solvent evaporation 
method. The method used was found to be reproducible for loading 
lipophilic drug within emulsomes. Ptx loaded emulsomes were 
optimized successfully to attain the desirable physicochemical 
properties in terms of size, shape, surface charge, drug entrapment 
efficiency and showed pH dependent drug release. The formulation 
was stable at physiological pH with minimum leakage of the drug. 
Hence, emulsomes are envisaged to protect the healthy tissue from 
the toxic effect of anticancer agent while in the systemic circulation. 
The faster release at acidic pH highlights their potential to deliver 
drugs specifically to the tumor site. The surface of emulsomes can be 
easily pegylated to formulate long circulatory nanocarriers and 
circumvent RES uptake. Moreover, phospholipid envelope can be 
tailored with a variety of ligand which widens the applicability of 
emulsomes in the field of targeted drug delivery to numerous 
receptors for the delivery of drug and biological molecules against 
several infections and disorders. The present preliminary study 
provides insight for the potential of sterically stabilized emulsome 
as a novel and non-toxic platform for the delivery of Paclitaxel and 
other poorly water-soluble drugs as well. 
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